Key Takeaways
  • SKQ1 is a mitochondria-targeted antioxidant expected to reduce reactive oxygen species (ROS) generated within eye cells.
  • Visomitin, an eye drop containing SKQ1, is approved as a pharmaceutical in Russia and has shown efficacy for dry eye in multicenter randomized trials (Advances in Therapy, 2015, etc.).
  • While animal studies suggest it may slow cataract progression, human evidence is limited to eye drops. Anti-aging effects from oral or topical use remain uncertain.
  • In our geefee team's experience, we noticed subjective improvements in eyesight over a short period, though individual differences and placebo effects are possible. We recommend consulting a doctor before use.

Introduction: What is SKQ1, the New Approach to Protecting Eye "Youth"?

We all realize that our eyesight and eye condition change as we age. Even if we take supplements like omega-3s or vitamins, it is difficult to address damage at the cellular level. This is where SKQ1, a mitochondria-targeted antioxidant, and Visomitin, the eye drop containing it, are drawing attention. In this article, we will gently summarize the mechanism, clinical data, our personal experience using it, and points to note.

The True Identity and Mechanism of Action of SKQ1

Antioxidant Targeting Mitochondria

SKQ1 is a molecule designed to transport plastoquinone into the mitochondria, developed by a research team led by Russian biochemist Dr. Vladimir P. Skulachev. While mitochondria produce a large amount of energy, they are prone to generating reactive oxygen species (ROS), and eye tissues like the retina are particularly susceptible to this. SKQ1 aims to protect cells by reducing ROS within the mitochondria and preventing the peroxidation of lipids such as cardiolipin.

Research and Effects of Visomitin (SKQ1 Eye Drops)

Human Clinical Data

Visomitin was approved as a pharmaceutical in Russia in 2011. In 2015, a multicenter randomized double-blind trial (reported in the journal Advances in Therapy) demonstrated stabilization of the tear film and improvement of corneal damage for dry eye syndrome. Many patients use it in Russia, and there have been no major reports of serious safety issues. On the other hand, pharmaceutical approval in the West and Japan is limited. There are reports that clinical trials are underway in the US, but it has not reached widespread approval (clinical trial data and review status are continuously updated, so please check with medical institutions for the latest information).

Implications from Animal Studies

In rats and senescence-accelerated models (OXYS rats), studies have shown that SKQ1 eye drops can slow the progression of cataracts and have a retina-protecting effect, raising expectations for future applications. However, it is important to note that animal data does not always directly apply to humans.

Our geefee Team's Experience — A Personal Report

One of our staff members (a male in his 50s, hereafter referred to as Reporter T) ordered Visomitin via personal import and tried it for about a week. The usage was 1 drop, 2 to 3 times a day. Around the 4th day, he reported feeling that the outlines of distant objects looked slightly sharper, and after that, he noticed less discomfort in his daily life. Currently, he maintains this condition with maintenance drops a few times a week. To be honest, self-reported improvements may involve a placebo effect, and it does not mean everyone will experience the same results. Still, realizing things like "my eyes feel less tired" or "the whites of my eyes seem brighter" was a surprise for us.

How to Use and Precautions (Safety and How to Obtain)

  • Consult an ophthalmologist before use: Please check with a doctor, especially if you wear contact lenses, are pregnant or breastfeeding, or have existing eye conditions.
  • Side effects: While no major adverse events have been widely reported in clinical trials, eye irritation, itching, or hypersensitivity may occur. If you notice any abnormalities, stop using it immediately and consult a doctor.
  • Risks of personal import: Importing from overseas for personal use involves risks regarding quality, storage conditions, and legal issues. If possible, obtain it through a legitimate medical institution or check the regulations before importing.
  • Setting expectations: Currently, established indications in humans are limited to certain conditions like dry eye, and it does not guarantee a cure for age-related diseases or dramatic "rejuvenation." Further verification through long-term data and large-scale independent trials is needed.

Conclusion

SKQ1 offers a unique approach by directly targeting mitochondria, and the eye drop Visomitin has promising clinical data for dry eye. While we felt short-term improvements in our own experience, there are individual differences and limitations to the research. It is worth paying attention to as a new treatment option, but we recommend consulting a doctor and checking the latest clinical information and regulatory status when using it. As large-scale trials and overseas approvals progress further, its position in the field of eye anti-aging will become clearer.

Disclaimer: The information in this article is for general informational purposes only and does not constitute medical advice. Please consult a qualified healthcare professional before making any health-related decisions.